Definium Therapeutics, Inc. (DFTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Definium Therapeutics, Inc. (DFTX) has a cash flow conversion efficiency ratio of -0.126x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.89 Million) by net assets ($332.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Definium Therapeutics, Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Definium Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Definium Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Definium Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Definium Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pandox AB (publ)
ST:PNDX-B
|
0.016x |
|
Bure Equity AB
ST:BURE
|
-0.006x |
|
Payoneer Global Inc
NASDAQ:PAYO
|
0.079x |
|
Glodon Software Co Ltd
SHE:002410
|
0.193x |
|
Gujarat Mineral Development Corporation Limited
NSE:GMDCLTD
|
0.036x |
|
Mobileye Global Inc. Class A Common Stock
NASDAQ:MBLY
|
0.009x |
|
Construcciones y Auxiliar de Ferrocarriles S.A.
MC:CAF
|
0.141x |
|
Transportadora de Gas del Sur SA ADR
NYSE:TGS
|
0.045x |
Annual Cash Flow Conversion Efficiency for Definium Therapeutics, Inc. (2015–2025)
The table below shows the annual cash flow conversion efficiency of Definium Therapeutics, Inc. from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Definium Therapeutics, Inc. (DFTX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $332.33 Million | $-131.56 Million | -0.396x | -20.79% |
| 2024-12-31 | $241.45 Million | $-79.13 Million | -0.328x | +60.22% |
| 2023-12-31 | $78.13 Million | $-64.36 Million | -0.824x | -147.95% |
| 2022-12-31 | $150.92 Million | $-50.14 Million | -0.332x | -9.96% |
| 2021-12-31 | $151.66 Million | $-45.82 Million | -0.302x | +2.86% |
| 2020-12-31 | $75.87 Million | $-23.60 Million | -0.311x | -309.18% |
| 2019-12-31 | $2.74 Million | $-208.12K | -0.076x | +62.91% |
| 2018-12-31 | $3.52 Million | $-722.45K | -0.205x | -21.47% |
| 2017-12-31 | $3.95 Million | $-665.98K | -0.169x | +19.37% |
| 2016-12-31 | $127.28K | $-26.64K | -0.209x | -27.73% |
| 2015-12-31 | $284.17K | $-46.56K | -0.164x | -- |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more